About US
Contact us
-
AbbVie scores 'game-changer' nod for Oriahnn in uterine fibroidsMost of the recent enthusiasm around AbbVie’s new drugs has centered on immunology meds Skyrizi and Rinvoq, but women’s health med elagolix—known commercially asOrilissain endometriosis—wants a piece2020/6/1
-
Sanofi loses vaccines chief Loew to Ipsen amid global attention on its COVID-19 projectSanofi’s new CEO Paul Hudson has beenmaking his mark in the company’s C-suite, and his latest round of executive shuffling will impact the company's top vaccines job—even as it’s preparing prepping i2020/6/1
-
In stomach cancer, AstraZeneca and Daiichi's Enhertu goes where Roche's Kadcyla couldn'tDaiichi Sankyo and partner AstraZeneca’s Enhertu previously wowed industry watchers with stellar clinical data in heavily pretreated breast cancer, leading to a speedyFDA nodat the end of 2019. Now,2020/5/29
-
Gilead CAR-T med Yescarta delivers 93% response rate in slow-growing lymphomaGilead Sciences is working to move CAR-T therapy Yescarta into other types of non-Hodgkin lymphoma (NHL), and if data from an interim trial look-in are any indication, it’s well on its way. In a phas2020/5/29
-
AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83%In mid-April, at the recommendation of an independent data monitoring committee, AstraZeneca unblinded a phase 3 trial of Tagrisso two years early. Now, the public is getting a look at what prompted2020/5/28
-
Merck's Keytruda doubles time to disease progression in certain colorectal cancer patientsThe results are out, and they’re practice-changing: Merck’s Keytruda can double the time to disease worsening in patients with certain types of colorectal cancer. The immuno-oncology star kept cancer2020/5/28
-
Pfizer, Merck KGaA's Bavencio lines up for bladder cancer edge with survival winIn a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data in post-chemo patients. In a phase 3 study, Bavencio (avel2020/5/27
-
Immunomedics' new CEO hits COVID-19 exit, takes $1M on his way outThe COVID-19 crisis has stalled clinical development activities and drug launches. Now, it has led to the sudden departure of a freshly appointed biopharma CEO. Just over a month afterjoining Immunom2020/5/26
-
Roche hooks up with Gilead for Actemra-remdesivir combo trial in COVID-19The COVID-19 pandemic created an unexpected boost for Roche when health facilities in China started snapping up its IL-6 inhibitor Actemra to treat dangerous complicationsin COVID-19 patients. Sale2020/5/26
-
Takeda receives China approval for Adcetris to treat lymphomaTakeda China has received approval from the country’s National Medical Products Administration (NMPA) for Adcetris (brentuximab vedotin) to treat relapsed or refractory systemic anaplastic large cell2020/5/25